Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Novo Nordisk

NYSE:NVOPharma

Bagsværd, Denmark, Denmark · Est. 1923 · 48,500 employees

Novo Nordisk is a global healthcare company specializing in diabetes care, obesity management, and other chronic diseases with a focus on insulin and GLP-1 receptor agonists.

32

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

36

Indications↗

Distinct diseases across all programs

1,353

Clinical Trials↗

All sponsored trials (all statuses)

75

Orange Book Patents

Across 4 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

32 drugs in development

Approved1

Phase 312

Phase 24

Phase 115

Preclinical7

By Therapeutic Area

top 6

Metabolic & Endocrine

1740%

Cardiovascular

512%

Hematology

512%

Nephrology

25%

Gastroenterology

25%

Rare Disease

12%

R&D Momentum

94/100

Pipeline Velocity

79/100

Trial Completion Rate

95/100

Pipeline Concentration

25/100

Pipeline Freshness

82/100

Strategic Signals

↗Active in Nephrology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Active, not recruiting

Open-label Study Investigating Efficacy, Safety and Pharmacokinetics of Concizumab Prophylaxis in Children Below 12 Years With Haemophilia A or B With or Without Inhibitors

An Open-label, Multi-centre, Rollover Study to Characterise Long-term Safety and Efficacy of Etavopivat in Adults, Adolescents and Children Who Have Sickle Cell Disease or Thalassaemia and Have Completed a Treatment Period in an Etavopivat Study

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Peroral Doses of Inno8 in People With Haemophilia A

Enrolling by invitation

A Real-world, Multi-centre, Prospective, Non-interventional, Single-arm Study Investigating Glycaemic Control, Treatment Satisfaction and Adherence Associated With the Switch From Daily Basal Insulin to Insulin Icodec in People Living With Type 2 Diabetes in Italy

A Global Phase 3, Randomised, Double-blind and Placebo-controlled Study Evaluating the Efficacy and Safety of Etavopivat in Adolescents and Adults With Sickle Cell Disease

Active, not recruiting

Efficacy and Safety of Concizumab Prophylaxis in Patients With Haemophilia A or B Without Inhibitors

Enrolling by invitation

Cities for Better Health Childhood Obesity Prevention Initiative: A Multi-country Community-based Prevention and Intervention Project Targeting Childhood Obesity Through Diet and Physical Activity Interventions in Disadvantaged Communities of Urban Areas

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Japanese Participants With Overweight or Obesity (AMAZE 10)

Active, not recruiting

Evaluation of Different Dose Escalation Regimens for NNC0662-0419 in Participants With Obesity

Enrolling by invitation

A Real-world, Multi-centre, Prospective, Non-interventional, Single-arm Study Investigating Glycaemic Control, Treatment Satisfaction and Adherence Associated With the Switch From Daily Basal Insulin to Insulin Icodec in People Living With Type 2 Diabetes in China

An Exploratory Study to Investigate Pain Related to Injection of Large Volumes (up to 5mL) Subcutaneously

Details

Company Info

Company Overview

$550.0B

Mkt Cap

$21.4B

Revenue

—

Cash

CEOLars Fruergaard Jørgensen

Founded1923

Employees48,500

HQBagsværd, Denmark, Denmark

ExchangeNYSE:NVO

Websitenovonordisk.com

LinkedInCompany Page

Therapeutic Focus

Metabolic & EndocrineOtherCardiovascularGastroenterologyOncologyMusculoskeletalPsychiatryInfectious DiseaseRespiratoryRare DiseaseNeurologyOphthalmologyHematologyNephrologyImmunology

Patent Expirations

20 patent groups across drugs · Source: FDA Orange Book

DrugExpires

VictozaAug 13, 2025 Ozempic11 patentsJan 20, 2026 VictozaFeb 13, 2026 Ozempic2 patentsFeb 27, 2027 Estrace3 patentsJul 10, 2028 EstraceJul 4, 2030 Ozempic5 patentsDec 5, 2031 OzempicFeb 1, 2032

12 more

Estrace19 patentsNov 21, 2032 Ozempic8 patentsMar 15, 2033 EstraceFeb 2, 2034 Ozempic3 patentsMay 2, 2034 Rivfloza4 patentsOct 9, 2035 Victoza2 patentsJan 9, 2037 OzempicApr 28, 2037 Ozempic6 patentsAug 24, 2038 Rivfloza2 patentsOct 12, 2038 Ozempic2 patentsFeb 1, 2039 OzempicMay 13, 2040 OzempicFeb 17, 2041

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(5 drugs)

—

1

1

3

—

Cardiovascular(5 drugs)

Gastroenterology(2 drugs)

—

2

—

—

—

Gastroenterology(2 drugs)

Hematology(5 drugs)

—

2

—

3

—

Hematology(5 drugs)

Metabolic & Endocrine(17 drugs)

3

9

1

5

1

Metabolic & Endocrine(17 drugs)

Nephrology(2 drugs)

—

1

1

—

—

Nephrology(2 drugs)

Rare Disease(1 drug)

1

—

—

—

—

Rare Disease(1 drug)

Unknown / Other(10 drugs)

5

1

3

4

—

Unknown / Other(10 drugs)

Regulatory

Regulatory Timeline

20073 events

FDAJul 27

Estrace — EVAMIST

Application NDA022014 (NDA)

FDAJul 27

Estrasorb — EVAMIST

Application NDA022014 (NDA)

FDAJun 4

Estrace — DIVIGEL

Application NDA022038 (NDA)

20092 events

FDANov 25

Estrace — VAGIFEM

Application NDA020908 (NDA)

FDANov 25

Estrasorb — VAGIFEM

Application NDA020908 (NDA)

20101 event

FDAJan 25

Victoza — VICTOZA

Application NDA022341 (NDA)

20143 events

FDADec 23

Victoza — SAXENDA

Application NDA206321 (NDA)

FDASep 23

Estrace — MINIVELLE

Application NDA203752 (NDA)

FDASep 23

Estrasorb — MINIVELLE

Application NDA203752 (NDA)

20151 event

FDASep 25

TRESIBA — TRESIBA

Application BLA203314 (BLA)

20173 events

FDADec 5

Ozempic — OZEMPIC

Application NDA209637 (NDA)

FDASep 29

FIASP — FIASP

Application BLA208751 (BLA)

FDASep 29

FIASP — FIASP

Application BLA208751 (BLA)

20182 events

FDAMay 29

Estrace — IMVEXXY

Application NDA208564 (NDA)

FDAMay 29

Estrasorb — IMVEXXY

Application NDA208564 (NDA)

20211 event

FDAJun 4

Ozempic — WEGOVY

Application NDA215256 (NDA)

20231 event

FDASep 29

Rivfloza — RIVFLOZA

Application NDA215842 (NDA)

20242 events

FDADec 20

ALHEMO — ALHEMO

Application BLA761315 (BLA)

FDADec 9

Ozempic — RYBELSUS

Application NDA213051 (NDA)

20251 event

FDADec 22

Ozempic — WEGOVY

Application NDA218316 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)